Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
HUTCHMED (China) ( (HK:0013) ) has issued an announcement.
HUTCHMED (China) Limited reported that all ordinary and special resolutions proposed at its May 12, 2026 annual general meeting were approved by shareholders, including the adoption of its 2025 financial statements and the re-election of multiple board directors. Shareholders also backed the reappointment of PricewaterhouseCoopers as auditors for both Hong Kong and U.S. reporting purposes, reinforcing continuity in the company’s financial oversight.
The meeting further authorized a general mandate for the board to issue additional shares and to repurchase company shares, providing HUTCHMED with added flexibility in capital management. Investors also approved the adoption of a 2026 Share Option Scheme, signaling support for the company’s compensation and incentive structure as it continues executing its growth and development strategy in the biopharmaceutical sector.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on discovering, developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. It advances drug candidates from in-house discovery to global markets, with three medicines already marketed in China and one also approved in the U.S., Europe and Japan.
See more data about 0013 stock on TipRanks’ Stock Analysis page.